论文部分内容阅读
目的:观察多西他赛单药治疗老年复发卵巢上皮癌的疗效、生活质量改变以及不良反应。方法:28例经病理学或细胞学确诊的老年复发卵巢上皮癌患者(≥60岁),应用多西他赛100mg·(m2)-1,静脉滴注,第1天给药,每21天为1周期;对照组给予最佳支持治疗(BSC)。结果:多西他赛治疗组有效率(RR)为32.1%,中位缓解时间为16.5个月,中位肿瘤进展时间(TTP)为11.6个月,中位生存期(OS)为22.4个月;对照组有效率(RR)为0%,中位TTP为5.3个月,中位OS为11.8个月。治疗组治疗后生存质量较治疗前及对照组均有明显提高(P<0.01)。治疗组药物不良反应较轻,无因不良反应需停药者。结论:多西他赛单药治疗老年复发卵巢上皮癌患者疗效确切,不良反应较轻,耐受性较好。
OBJECTIVE: To observe the efficacy, quality of life and side effects of docetaxel monotherapy in the treatment of elderly recurrent epithelial ovarian cancer. Methods: 28 patients with pathologically or cytologically diagnosed elderly patients with recurrent epithelial ovarian cancer (≥60 years old) were treated with docetaxel 100 mg · (m2) -1 intravenously, on the first day, every 21 days 1 cycle; control group given the best supportive care (BSC). Results: The docetaxel treatment group had an effective rate (RR) of 32.1%, a median response time of 16.5 months, a median tumor progression time (TTP) of 11.6 months and a median OS of 22.4 months ; The control group was 0% effective rate (RR), the median TTP was 5.3 months, the median OS was 11.8 months. The quality of life of the treatment group after treatment was significantly higher than that before treatment and the control group (P <0.01). Adverse drug reactions in the treatment group were lighter, no due to adverse reactions should be discontinued. Conclusion: Docetaxel monotherapy for the treatment of elderly patients with recurrent epithelial ovarian cancer has definite curative effect, less adverse reactions and better tolerability.